PARP1 and acute myeloid leukemia: mRNA expression data from patients with AML with FAB subtypes M1 and M2 (n = 231) and M4 and M5 (n = 210) receiving curative treatment including 7+3 chemotherapy with ara-C and idarubicin were stratified into three equal groups based on their relative expression levels of PARP1 mRNA (low: 0%–33%; middle: 33%–66%; and high: 66%–100%).